Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 7/2020

Open Access 01-07-2020 | Thyroid Cancer | Review

Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review

Authors: Andrés Coca-Pelaz, Jatin P. Shah, Juan C. Hernandez-Prera, Ronald A. Ghossein, Juan P. Rodrigo, Dana M. Hartl, Kerry D. Olsen, Ashok R. Shaha, Mark Zafereo, Carlos Suarez, Iain J. Nixon, Gregory W. Randolph, Antti A. Mäkitie, Luiz P. Kowalski, Vincent Vander Poorten, Alvaro Sanabria, Orlando Guntinas-Lichius, Ricard Simo, Peter Zbären, Peter Angelos, Avi Khafif, Alessandra Rinaldo, Alfio Ferlito

Published in: Advances in Therapy | Issue 7/2020

Login to get access

Abstract

Introduction

Aggressive variants of papillary thyroid cancer (PTC) have been described with increasing frequency. These variants include diffuse sclerosing variant, tall cell variant, columnar cell variant, solid variant, and hobnail variant.

Methods

We have performed a review of the more aggressive variants of PTC with respect to main characteristics, histological and molecular features, and the consequences that the knowledge of these variants should have in the treatment of the patients.

Results

At the present time, we do not know the prognostic value of these aggressive PTC variants. The extent of the surgical treatment and adjuvant therapy necessary should be decided on the basis of the extent of the tumor at presentation and the opinion of experienced clinicians.

Conclusion

These aggressive variants should be known by clinicians, to avoid underdiagnosis, and treated according to the latest recommendations in the literature.
Literature
1.
Lloyd R, Osamura R, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
2.
3.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.PubMedPubMedCentralCrossRef
4.
Lam AK-Y, Lo C-Y, Lam KS-L. Papillary carcinoma of thyroid: a 30-year clinicopathological review of the histological variants. Endocr Pathol. 2005;16:323–30.PubMedCrossRef
5.
Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31:916–23.PubMedCrossRef
6.
Vickery AL, Carcangiu ML, Johannessen JV, Sobrinho-Simoes M. Papillary carcinoma. Semin Diagn Pathol. 1985;2:90–100.PubMed
7.
Chow S-M, Chan JKC, Law SCK, et al. Diffuse sclerosing variant of papillary thyroid carcinoma—clinical features and outcome. Eur J Surg Oncol. 2003;29:446–9.PubMedCrossRef
8.
Pillai S, Gopalan V, Smith RA, Lam AK-Y. Diffuse sclerosing variant of papillary thyroid carcinoma—an update of its clinicopathological features and molecular biology. Crit Rev Oncol Hematol. 2015;94:64–73.PubMedCrossRef
9.
Lam AKY, Lo CY. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol. 2006;13:176–81.PubMedCrossRef
10.
Falvo L, Giacomelli L, D’Andrea V, Marzullo A, Guerriero G, de Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg. 2006;72:438–44.PubMed
11.
Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol. 2012;19:1874–80.PubMedCrossRef
12.
Fridman MV, Savva NN, Krasko OV, et al. Clinical and pathologic features of “sporadic” papillary thyroid carcinoma registered in the years 2005 to 2008 in children and adolescents of Belarus. Thyroid. 2012;22:1016–24.PubMedCrossRef
13.
Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991–1992) from the Republic of Belarus. Cancer. 1994;74:748–66.PubMedCrossRef
14.
Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. 2011;21:383–9.PubMedCrossRef
15.
Vuong HG, Kondo T, Pham TQ, et al. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:433–41.PubMedCrossRef
16.
Takagi N, Hirokawa M, Nobuoka Y, Higuchi M, Kuma S, Miyauchi A. Diffuse sclerosing variant of papillary thyroid carcinoma: a study of fine needle aspiration cytology in 20 patients. Cytopathology. 2014;25:199–204.PubMedCrossRef
17.
Koo JS, Shin E, Hong SW. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma. APMIS. 2010;118:744–52.PubMedCrossRef
18.
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2011;33:1052–9.PubMedCrossRef
19.
Sheu S-Y, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol. 2007;20:779–87.PubMedCrossRef
20.
Joung JY, Kim TH, Jeong DJ, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. Histopathology. 2016;69:45–53.PubMedCrossRef
21.
Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK-Y. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol. 2011;42:500–6.PubMedCrossRef
22.
Lin X, Finkelstein SD, Zhu B, Silverman JF. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol. 2008;41:195–203.PubMedCrossRef
23.
Lee J-H, Lee ES, Kim Y-S, Won NH, Chae Y-S. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology. 2006;38:201–4.PubMedCrossRef
24.
Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid. 2013;23:1423–30.PubMedCrossRef
25.
Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44–52.PubMedCrossRef
26.
Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844–50.PubMedCrossRef
27.
Sheu S-Y, Grabellus F, Schwertheim S, Handke S, Worm K, Schmid KW. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Horm Metab Res. 2009;41:482–7.PubMedCrossRef
28.
Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q. 1976;43:207–15.PubMedCrossRef
29.
Crile G, Hazard JB, Dinsmore RS. Carcinoma of the thyroid gland, with special reference to a clinicopathologic classification. J Clin Endocrinol Metab. 1948;8:762–5.PubMedCrossRef
30.
Ganly I, Ibrahimpasic T, Rivera M, et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid. 2014;24:662–70.PubMedCrossRef
31.
Beninato T, Scognamiglio T, Kleiman DA, et al. Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma. Surgery. 2013;154:1331–6.PubMedCrossRef
32.
Oh WJ, Lee YS, Cho U, et al. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. Korean J Pathol. 2014;48:201–8.PubMedPubMedCentralCrossRef
33.
34.
Wang X, Cheng W, Liu C, Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget. 2016;7:40792–9.PubMedPubMedCentralCrossRef
35.
Gunalp B, Okuyucu K, Ince S, Ayan A, Alagoz E. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients. Hell J Nucl Med. 2017;20:122–7.PubMed
36.
Morris LGT, Shaha AR, Tuttle RM, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20:153–8.PubMedPubMedCentralCrossRef
37.
Nath MC, Erickson LA. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. Adv Anat Pathol. 2018;25:172–9.PubMedCrossRef
38.
Russo M, Malandrino P, Moleti M, et al. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. J Endocrinol Invest. 2017;40:1235–41.PubMedCrossRef
39.
Vuong HG, Long NP, Anh NH, et al. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis. Endocr Connect. 2018;7:R286–93.PubMedPubMedCentralCrossRef
40.
Bongers PJ, Kluijfhout WP, Verzijl R, et al. Papillary thyroid cancers with focal tall cell change are as aggressive as tall cell variants and should not be considered as low-risk disease. Ann Surg Oncol. 2019;26:2533–9.PubMedCrossRef
41.
Wong KS, Higgins SE, Marqusee E, Nehs MA, Angell T, Barletta JA. Tall cell variant of papillary thyroid carcinoma: impact of change in WHO definition and molecular analysis. Endocr Pathol. 2019;30:43–8.PubMedCrossRef
42.
Hernandez-Prera JC, Machado RA, Asa SL, et al. Pathologic reporting of tall-cell variant of papillary thyroid cancer: have we reached a consensus? Thyroid. 2017;27:1498–504.PubMedCrossRef
43.
Solomon A, Gupta PK, LiVolsi VA, Baloch ZW. Distinguishing tall cell variant of papillary thyroid carcinoma from usual variant of papillary thyroid carcinoma in cytologic specimens. Diagn Cytopathol. 2002;27:143–8.PubMedCrossRef
44.
Das DK, Mallik MK, Sharma P, et al. Papillary thyroid carcinoma and its variants in fine needle aspiration smears. A cytomorphologic study with special reference to tall cell variant. Acta Cytol. 2004;48:325–36.PubMedCrossRef
45.
Erler P, Keutgen XM, Crowley MJ, et al. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer. Surgery. 2014;156:1342–50 (discussion 1350).PubMedCrossRef
46.
Basolo F, Giannini R, Monaco C, et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol. 2002;160:247–54.PubMedPubMedCentralCrossRef
47.
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.CrossRef
48.
Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol. 2004;86:44–54.PubMedCrossRef
49.
Gaertner EM, Davidson M, Wenig BM. The columnar cell variant of thyroid papillary carcinoma. Case report and discussion of an unusually aggressive thyroid papillary carcinoma. Am J Surg Pathol. 1995;19:940–7.PubMedCrossRef
50.
Sujoy V, Pinto A, Nosé V. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression. Thyroid. 2013;23:714–9.PubMedCrossRef
51.
Enriquez ML, Baloch ZW, Montone KT, Zhang PJ, LiVolsi VA. CDX2 expression in columnar cell variant of papillary thyroid carcinoma. Am J Clin Pathol. 2012;137:722–6.PubMedCrossRef
52.
Wenig BM, Thompson LD, Adair CF, Shmookler B, Heffess CS. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer. 1998;82:740–53.PubMedCrossRef
53.
Cho J, Shin JH, Hahn SY, Oh YL. Columnar cell variant of papillary thyroid carcinoma: ultrasonographic and clinical differentiation between the indolent and aggressive types. Korean J Radiol. 2018;19:10–5.CrossRef
54.
Chen J-H, Faquin WC, Lloyd RV, Nosé V. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol. 2011;24:739–49.PubMedCrossRef
55.
Wang S, Xiong Y, Zhao Q, Song H, Yi P, Liu C. Columnar cell papillary thyroid carcinoma prognosis: findings from the SEER database using propensity score matching analysis. Am J Transl Res. 2019;11:6262–70.PubMedPubMedCentral
56.
Jiang C, Cheng T, Zheng X, et al. Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis. Cancer Manag Res. 2018;10:465–72.PubMedPubMedCentralCrossRef
57.
Bongiovanni M, Mermod M, Canberk S, et al. Columnar cell variant of papillary thyroid carcinoma: cytomorphological characteristics of 11 cases with histological correlation and literature review. Cancer Cytopathol. 2017;125:389–97.PubMedCrossRef
58.
Rottuntikarn W, Wangsiricharoen S, Rangdaeng S. Cytomorphology and immunocytochemistry of columnar cell variant of papillary thyroid carcinoma. Cytopathology. 2017;28:338–41.PubMedCrossRef
59.
Sak SD. Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor. Turk Patol Derg. 2015;31(Suppl 1):34–47.
60.
Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985;55:805–28.PubMedCrossRef
61.
Damle N, Ramya S, Bal C, Durgapal P. Solid variant of papillary carcinoma thyroid in a child with no history of radiation exposure. Indian J Nucl Med. 2011;26:196–8.PubMedPubMedCentralCrossRef
62.
Chang H, Kim SM, Chun KW, et al. Clinicopathologic features of solid variant papillary thyroid cancer. ANZ J Surg. 2014;84:380–2.PubMedCrossRef
63.
Guleria P, Phulware R, Agarwal S, et al. Cytopathology of solid variant of papillary thyroid carcinoma: differential diagnoses with other thyroid tumors. Acta Cytol. 2018;62:371–9.PubMedCrossRef
64.
Sebastian SO, Gonzalez JM, Paricio PP, et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg. 2000;135:272–7.PubMedCrossRef
65.
Vander Poorten V, Hens G, Delaere P. Thyroid cancer in children and adolescents. Curr Opin Otolaryngol Head Neck Surg. 2013;21:135–42.PubMedCrossRef
66.
67.
Vuong HG, Odate T, Duong UNP, et al. Prognostic importance of solid variant papillary thyroid carcinoma: a systematic review and meta-analysis. Head Neck. 2018;40:1588–97.PubMedCrossRef
68.
Ohashi R, Kawahara K, Namimatsu S, et al. Clinicopathological significance of a solid component in papillary thyroid carcinoma. Histopathology. 2017;70:775–81.PubMedCrossRef
69.
Ohashi R, Murase Y, Matsubara M, et al. Fine needle aspiration cytology of the papillary thyroid carcinoma with a solid component: a cytological and clinical correlation. Diagn Cytopathol. 2017;45:391–8.PubMedCrossRef
70.
Trovisco V, Soares P, Soares R, Magalhães J, Sá-Couto P, Sobrinho-Simões M. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol. 2005;36:694–7.PubMedCrossRef
71.
Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A. Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. J Clin Pathol. 2004;57:1041–6.PubMedPubMedCentralCrossRef
72.
Motosugi U, Murata S-I, Nagata K, Yasuda M, Shimizu M. Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid. 2009;19:535–7.PubMedCrossRef
73.
Asioli S, Erickson LA, Righi A, Lloyd RV. Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. Hum Pathol. 2013;44:320–8.PubMedCrossRef
74.
Lubitz CC, Economopoulos KP, Pawlak AC, et al. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid. 2014;24:958–65.PubMedPubMedCentralCrossRef
75.
Amacher AM, Goyal B, Lewis JS, El-Mofty SK, Chernock RD. Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma: a possible manifestation of high-grade transformation. Am J Surg Pathol. 2015;39:260–5.PubMedCrossRef
76.
Asioli S, Maletta F, Pagni F, et al. Cytomorphologic and molecular features of hobnail variant of papillary thyroid carcinoma: case series and literature review. Diagn Cytopathol. 2014;42:78–84.PubMedCrossRef
77.
Morandi L, Righi A, Maletta F, et al. Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. Endocr Relat Cancer. 2017;24:107–17.PubMedCrossRef
78.
Ambrosi F, Righi A, Ricci C, Erickson LA, Lloyd RV, Asioli S. Hobnail variant of papillary thyroid carcinoma: a literature review. Endocr Pathol. 2017;28:293–301.PubMedCrossRef
79.
Wong KS, Chen TY, Higgins SE, et al. A potential diagnostic pitfall for hobnail variant of papillary thyroid carcinoma. Histopathology. 2019;76:707–13.CrossRef
80.
Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113:48–56.PubMedCrossRef
81.
Malandrino P, Russo M, Regalbuto C, et al. Outcome of the diffuse sclerosing variant of papillary thyroid cancer: a meta-analysis. Thyroid. 2016;26:1285–92.PubMedCrossRef
82.
Yamashita H, Noguchi S, Takahashi H, et al. The diffuse sclerosing variant of papillary thyroid carcinoma is not an aggressive subtype of papillary carcinoma. J Thyroid Disord Ther. 2014;3:163.
83.
Metadata
Title
Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review
Authors
Andrés Coca-Pelaz
Jatin P. Shah
Juan C. Hernandez-Prera
Ronald A. Ghossein
Juan P. Rodrigo
Dana M. Hartl
Kerry D. Olsen
Ashok R. Shaha
Mark Zafereo
Carlos Suarez
Iain J. Nixon
Gregory W. Randolph
Antti A. Mäkitie
Luiz P. Kowalski
Vincent Vander Poorten
Alvaro Sanabria
Orlando Guntinas-Lichius
Ricard Simo
Peter Zbären
Peter Angelos
Avi Khafif
Alessandra Rinaldo
Alfio Ferlito
Publication date
01-07-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 7/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01391-1

Other articles of this Issue 7/2020

Advances in Therapy 7/2020 Go to the issue

Correction

Correction to: Panel Discussion: Some Aspects of the Management of Patients with X-Linked Hypophosphataemic Rickets

Original Research

Persistence of Inflammation After Uncomplicated Cataract Surgery: A 6-Month Laser Flare Photometry Analysis

Brief Report

Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis

Original Research

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Original Research

Development and Validation of a Nomogram-Based Prognostic Evaluation Model for Sarcomatoid Hepatocellular Carcinoma

Original Research

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3–11 Years with Hepatitis C Genotype 1a

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits